KeyVibe and KEYFORM Clinical Programs of Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab to be discontinued December 18, 2024
Reprioritized pipeline focus on LAVA-1266 and plan to discontinue development of LAVA-1207 December 18, 2024
Efficacy threshold not achieved in Ph 1 dose escalation trial for FHD-286 + decitabine to support continued development in patients with R/R AML December 18, 2024
DSMB recommends continuation of Ph 3 study of Bria-IMT™ + an immune checkpoint inhibitor in metastatic breast cancer patients December 10, 2024
Doses Selected for Ph 1b Expansion Trials Supported by Efficacy & Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in metastatic CRPC December 10, 2024
First Patient Enrolled in Taiwan for Ph 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC Patients December 10, 2024
First Patient Dosed in Ph 3 Clinical trial of HLX22/AC101 in 1L HER2-positive advanced gastric/GEJ cancer December 10, 2024
Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms completed in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast Cancer December 10, 2024
Patient Enrollment Expanded for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM as UVA Cancer Center Doses First Patient December 4, 2024
First patient dosed in Ph 3 trial HLX22-GC-301 of HLX22 in combination with trastuzumab and chemo in 1L HER2+ve advanced G/GEJ cancer patients November 26, 2024
First Patient Dosed in Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies November 26, 2024
Enrollment of 68 patients completed in Ph 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule November 26, 2024
TUSCANY Ph 1/2 Study for Newly Diagnosed AML Patients Initiated to Receive Tuspetinib-based Triplet Therapy November 26, 2024
First Patient Enrolled in Ph 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors November 26, 2024
First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers November 26, 2024
SRN-101 announced as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA November 26, 2024
